0.00
0.00%
Close of 2 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BG Medicine
Its shares trade under the ticker BGMD. It has been listed since 4 February 2011. In the fiscal year to 31 December 2015, it reported revenue of $1.6m and a net loss of $5.3m. At that date it held total assets of $2.1m and shareholders' equity of −$2.0m.
BG Medicine, Inc. is a life sciences company. The company is headquartered in Waltham, Massachusetts. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 4 Feb 2011
- Employees
- 5
- Website
- bg-medicine.com/contact-us ↗
Leadership
Pay as last reported
- Mr. Harry WilcoxChairman of the Board, since 2015
- Dr. Paul SohmerPresident, Chief Executive Officer, Director, since 2013$568,899
- Mr. Stephen HallChief Financial Officer, Executive Vice President, Treasurer$448,840
- Dr. Aram AdourianSenior Vice President, Chief Scientific Officer$372,812
- Mr. Jeffrey LuberIndependent Director
- Mr. James O'ConnorIndependent Director
- Dr. Stelios PapadopoulosIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company has a focused product portfolio including BGM Galectin-3 Test and CardioSCORE test.
- Operates with a small team of 5 full-time employees.
- Has a clear commercialization strategy for diagnostic products in heart failure management.
Weaknesses
- Limited employee count of only 5 full-time employees.
- Relies on partners for automated galectin-3 test development and commercialization.
- No mention of revenue or market share data in provided information.
Opportunities
- Potential growth in heart failure diagnostic market with increasing prevalence of cardiovascular diseases.
- Expansion of automated test offerings through partner collaborations.
- Opportunity to leverage existing diagnostic products for broader clinical applications.
Threats
- Dependence on third-party partners for key product development and commercialization.
- Competition in the diagnostic testing market for heart failure management.
- Lack of detailed financial information may hinder investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.